The Department of Defense has awarded Novavax $60 million for the manufacturing of its COVID-19 vaccine candidate NVX-CoV2373.

Under the contract, the company will work with U.S.-based biologics contract development manufacturing organizations to manufacture the antigen and adjuvant components of the vaccine.

The funding also includes a delivery of 10 million doses this year that can be used in phase 2/3 clinical trials or under Emergency Use Authorization from the FDA.